A new biotech company co-located in Denmark and Belgium, has been launched with €60 million in Series A funding to investigate potential small molecule therapies for neurodegenerative disorders including Alzheimer’s disease. Muna Therapeutics draws on the expertise of scientists from Aarhus University in Denmark and KU Leuven in Belgium. Early entrepreneurial support was provided by Novo Seeds, a unit of the Novo Holdings A/S investment group.
